Evidence map›Paper›PMID 40264678›Full record

ArticleFrontiers in pharmacology2025

Baicalin reduces sunitinib-induced cardiotoxicity in renal carcinoma PDX model by inhibiting myocardial injury, apoptosis and fibrosis.

Zefu Yang, Jianping Wan, Xinjin Zhang, Jiaqi Mei, Hua Hao, Sibo Liu, Yun Yi, Meixiu Jiang, Yuanqiao He

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zefu YangCardiovascular Medicine Department of Nanhai District People's Hospital, Foshan, Guangdong, China.
Jianping WanElectrophysiology Department of The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, China.
Xinjin ZhangCardiovascular Center, Affiliated Hospital of Yunnan University, Kunming, China.
Jiaqi MeiDepartment of Hematology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Hua HaoDepartment of Pathology, Yangpu District Central Hospital, School of Medicine, Tongji University, Shanghai, China.
Sibo LiuThe Queen MARY school, Jiangxi Medical College, Nanchang University, Nanchang, China.
Yun YiCenter of Biobank, Nanchang University Second Affiliated Hospital, Jiangxi Medical College, Nanchang, China.
Meixiu JiangThe Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, China.
Yuanqiao HeCenter of Laboratory Animal Science, Nanchang University, Nanchang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sunitinib (SU), a multi-targeted tyrosine kinase inhibitor, has anticancer function but its clinical use is often limited by cardiovascular complications. Baicalin (BA) has demonstrated various pharmacological activities including antioxidant, anti-inflammatory and antiviral properties, but its potential roles in SU-induced cardiotoxicity have not been reported. In this study, we aimed to investigate the effect of BA in SU-induced cardiotoxicity

Indexed as

baicalincardiotoxicityPDXrenal carcinomasunitinib

Identifiers

PMID40264678
PMCPMC12011809

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.